GeoVax Labs (GOVX) Cash & Equivalents (2010 - 2026)

GeoVax Labs (GOVX) has reported Cash & Equivalents for 17 consecutive years, with $3.1 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents rose 1.6% year-over-year to $3.1 million; the TTM figure through Jun 2026 stood at $3.1 million (up 1.6% YoY), while the FY2025 annual figure was $3.1 million, down 43.97% from the prior year.
• Cash & Equivalents grew to $3.1 million in Q2 2026 per GOVX's latest filing, from $3.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $34.7 million in Q3 2022 and bottomed at $768859.0 in Q1 2024.
• Historically, Cash & Equivalents has averaged $12.3 million across 5 years, with a median of $7.4 million in 2025.
• Annual changes were most pronounced in 2024 — Cash & Equivalents tumbled 96.78% — and 2025, when it jumped 867.51%.
• GeoVax Labs' Cash & Equivalents stood at $27.6 million in 2022, then plunged by 76.63% to $6.5 million in 2023, then slipped by 14.66% to $5.5 million in 2024, then sank by 43.97% to $3.1 million in 2025, then increased by 1.87% to $3.1 million in 2026.
• Business Quant data shows GOVX's Cash & Equivalents at $3.1 million in Q2 2026, $3.1 million in Q4 2025, and $5.0 million in Q3 2025.